Abstract: FR-PO239
GFR in the Era of Precision Medicine: A Face to Face Between Measured GFR (mGFR) and Estimated GFR (eGFR) in Onconephrology
Session Information
- Onconephrology: From AKI to CKD and Everything in Between
November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Onconephrology
- 1700 Onconephrology
Authors
- Trevisani, Francesco, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
- Quattrini, Giulia, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
- Cinque, Alessandra, Biorek srl, Milan, Italy
- Capitanio, Umberto, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
- Laurenti, Fabiana, Universita degli Studi dell'Aquila - Polo Coppito, L'Aquila, Abruzzo, Italy
- Salonia, Andrea, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
- Bettiga, Arianna, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
- Pizzagalli, Giorgio, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
- Montorsi, Francesco, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
- Di Marco, Federico, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
Background
Onco-nephrological patients deserve the highest attention in term of personalized medicine. Acute and chronic renal damages represent common major side effects, often as a results of drugs renal toxicities due to false dosage based on GFR. Therefore, a reliable assessment of renal function is mandatory. Aim of this study was to determine the extent of the error of eGFR common formulas compared to mGFR in onco-nephrology.
Methods
A consecutive cohort of 701 onco-nephrological patients (pts) was collected to compare the most used eGFR formulas (MDRD, CKD-EPI SCr 2012, CKD-EPI 2021 SCr, CKD-EPI Cys 2012, CKD-EPI Cys 2021, CKD-EPI Cys/SCr, Cockroft-Gault) with mGFR method (Iohexol Plasma Clearance). True positives and False positives were classified in CKD stages based on eGFR and mGFR. Comparisons between groups were performed using Wilcoxon ranks sum test for numerical variables and Pearson's Chi square test for categorical ones.
Results
Clinical data: overall median age was 66 years, median BMI 25, Male: 536, F: 165, Diabetes: 10.9%, Hypertension: 53.8%, CKD stage I: 3.7%, II: 25.5%, IIIA: 28%, IIIB: 27.5%, IV: 13.4%, V: 1.74%, mean Creatinine: 1,44 mg/dl, cystatin: 1,24. We reported a huge discrepancy between the eGFR formulas and mGFR values, suggesting the essential role of mGFR in the clinical decision making algorithm (Figures 1 and 2).
Conclusion
eGFR formulas showed a non-negligible error in all CKD stages classification in comparison to mGFR. In the onconephrological asset, the use of mGFR should be mandatory to obtain a tailored management.